A role for interferon-β in Guillain-Barre syndrome?

BioDrugs

Volumn 14, Issue 1, 2000, Pages 1-11

  Créange, Alain ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CYTOKINE; GELATINASE B; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; CLINICAL TRIAL; DEMYELINATING DISEASE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

EID: 0033881380     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014010-00001     Document Type: Review

References (129)

1. Efficiency of plasma exchange in Guillain-Barre syndrome: Role of replacement fluids
2. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre Syndrome
3. Appropriate number of plasma exchanges in Guillain-Barre syndrome
4. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome
5. Guillain-Barre syndrome, CIDP and other chronic immune-mediated neuropathies
6. Plasmapheresis and acute Guillain-Barre syndrome
7. A trial of etanercept, A recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
8. Infliximab: A novel chimeric monoclonal antibody for the treatment of Crohn's disease [discussion 1]
9. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double blind, placebo-controlled trial
10. Immunopathogenesis and treatment of the Guillain-Barre syndrome: Part I
11. Macrophage systems in peripheral nerves: A review
12. Demyelination in vitro by Guillain-Barre syndrome and other human serum
13. Passive transfer studies in Guillain-Barre polyneuropathy
14. Demyelination induced by serum from patients with Guillain-Barre syndrome
15. Activite demyelinisante serique et syndrome de Guillain-Barre: Effet favorable des echanges plasmatiques
16. In vivo demyelinating activity of serum from patients with Guillain-Barre syndrome
17. Acute conduction block associated with experimental antiserum mediated demyelination of peripheral nerve
18. In vivo effects of sera from Guillain-Barre subgroups: An electrophysiological and histological study on rat nerves
19. Pathogenesis of inflammatory demyelination: Implications for therapy
20. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miler Fisher syndrome
21. Serum antibodies to gangliosides in Guillain-Barre syndrome
22. Anti-peripheral nerve myelin antibodies in Guillain-Barre syndrome bind a neutral glycolipid of peripheral myelin and cross-react with Forssmanantigen
23. Guillain-Barre syndrome associated with high titers of anti-GM1 antibodies
24. Structure and localization of gangliosides
25. Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barre syndrome
26. Antibodies to gangliosides and galactocerebroside in patients with Guillain-Barre syndrome with preceding Campylobacter jejuni and other identified infections
27. Characterization of Campylobacter jejuni isolates from patients with Guillain-Barre syndrome
28. Penner's serotype 4 of Campylobacter jejuni has a lipopolysaccharide that bears a GM1 ganglioside epitopee as well as one that bears a GD1a epitope
29. Acute motor axonal neuropathy: An antibody-mediated attack on axolemma
30. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: A macro-patch-clamp study
31. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome
32. The inflammatory lesion in idiopathic polyneuritis
33. Serum interleukin-2 concentrations in Guillain-Barre syndrome and chronic idiopathic demyelinating polyradiculoneuroapthy: Comparison with other neurological diseases of presumed immunopathogenesis
34. Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barre syndrome
35. Tumor necrosis factor mediates myelin and oligodendrocytes damage in vitro
36. Vascular changes and demyelination induced by the intraneural injection of tumour necrosis factor
37. Nerve lesions induced by macrophage activation
38. Potential role of transforming growth factor-b1 in terminating the immune response in patients with Guillain-Barre syndrome
39. Circulating transforming growth factor-beta 1 (TGF-β1) in Guillain-Barre syndrome: Decreased levels in the early course and increase with motor function
40. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease
41. Immune dysregulation in TGF-β1 deficient mice
42. Transforming growth factor-β1 modulates the expression of class II histocompatibility antigens on human cells
43. Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor β after antigen-specific triggering
44. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
45. Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-β1
46. Deactivation of macrophages by transforming growth factor-β
47. Oral administration of type I interferon β modulates the course of experimental allergic neuritis
48. Leukaemia inhibitory factor promotes the neuronal development of spinal cord precursors from the neural tube
49. Transforming growth factor-beta 1 regulates axon/Schwann cell interactions
50. Transforming growth factor beta has neurotrophic actions on sensory neurons in vitro and is synergistic with nerve growth factor
51. Signals and receptors involved in recruitment of inflammatory cells
52. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm
53. Serum levels of soluble E-selectin (ELAM-1) in immune-mediated neuropathies
54. Inhibition of the adhesion step of leukodiapedesis: A critical event in the recovery of Guillain-Barre syndrome associated with accumulation of proteolytically active lymphocytes in blood
55. The matrix metalloproteinases and their inhibitors
56. Leucocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein
57. Matrix metallo proteinase-9 is increased and correlates with disease severity in Guillain-Barre syndrome
58. The role of interferon-gamma in the pathogenesis of experimental autoimmune disease of the peripheral nervous system
59. Transforming growth factor-β1 in experimental autoimmune neuritis: Cellular localization and time course
60. The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat
61. A combined inhibitor of matrix metalloproteinase activity and tumor necrosis factor-α processing attenuates experimental autoimmuneuritis
62. Matrix metalloproteinase expression during experimental autoimmune neuritis
63. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination
64. Therapeutic effect of transforming growth factor-β2 on actively induced EAN but not adoptive transfer EAN
65. Suppression of experimental allergic neuritis by an antibody to the intercellular adhesion molecule ICAM-1
66. Chronic motor neuropathies: Response to interferon-beta1 a after failure of conventional therapies
67. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy
68. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy
69. IFN-beta suppresses experimental autoimmune neuritis in Lewis rats by inhibiting the migration of inflammatory cells into peripheral nervous tissue
70. Treatment of Guillain-Barre syndrome with interferon-beta
71. Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelines
72. Intravenous immunoglobulins and transforming growth factor beta
73. Interferons in multiple sclerosis: A review of the evidence
74. Interferon-β decreases T cell activation and interferon gamma production in multiple sclerosis
75. The interferons: Biological effects, mechanisms of action, and use in multiple sclerosis
76. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta
77. Virus-induced interferon alpha/beta (IFN-alpha/beta) production by T cells and by Th1 and Th2 helper T cell clones: A study of the immunoregulatory actions of IFN-gamma versus IFN-alpha/beta on functions of different T cell populations
78. Interferon beta modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion
79. Interferon beta induces T-helper 2 immune deviation in MS
80. Type I interferons enhance production of IFN-gamma by NK cells
81. Interferons
82. + B cells in active multiple sclerosis and reversal by interferon β-1b therapy
83. Selective inhibition of human glial inducible nitric oxide synthase by interferon-beta: Implications for multiple sclerosis
84. Interferon beta in the treatment of multiple sclerosis. Mechanisms of action
85. Recombinant interferon-γ increases HLA-DR synthesis and expression
86. Inteferon-b downregulates interferon-g-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells
87. Beta interferon prevents HLA class II antigen induction by gamma interferon in MS
88. Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo β-interferon
89. Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted
90. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients
91. Decreases in T-cell tumor necrosis factor a binding with interferon beta treatment in patients with multiple sclerosis
92. Interferon beta induces interleukin- 10 expression: Relevance to multiple sclerosis
93. Immunomodulatory effects of interferon-beta-1b in vivo: Induction of the expression of transforming growth factor-beta1 and its receptor type II
94. T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis
95. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells
96. Interferon-beta inhibits Th 1 responses at the dendritic cell level: Relevance to multiple sclerosis
97. Interferon gamma producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis
98. Antagonism of interferon beta on interferon gamma: Inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients
99. IFN-beta interferes with the differentiation of dendritic cells from peripheral blood mononuclear cells: Selective inhibition of CD40-dependent interleukin-12 secretion
100. Recent advances immunology in multiple sclerosis
101. Interferon-beta not only inhibits interleukin-1b and tumor necrosis factor-a but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells
102. IFNs are critical regulators of IL-1 receptor antagonist and IL-1 expression in human microglia
103. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development
104. Tissue-specific homing receptor mediates lymphocyte adhesion to cytokine-stimulated lymph node high endothelial venule cells
105. IFN induction and associated changes in splenic leukocyte distribution
106. Effect of interferon on thoraci duct lymphocyte output: Induction with either poly I: Poly C or vaccinia virus
107. Human recombinant interferon-beta influences T helper subset differentiation by regulating cytokine secretion pattern and expression of homing receptors
108. Intefferon-alpha and dexamethasone inhibit adhesion of T cells to endothelial cells and synovial cells
109. Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: An in vivo and in vitro study
110. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β-1b
111. Interferon beta-lb decreases the migration of T lymphocytes in vitro: Effects on matrix metalloproteinase-9
112. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis
113. Down-regulation of interferon-g-induced class II expression on human glioma cells by recombinant inteferon-β: Effects of dosage treatment schedule
114. Rationale for immunotherapy in multiple sclerosis
115. Interferon β in multiple sclerosis: Is IL-12 suppression the key?
116. Pretreatment of astrocytes with interferon-alpha/beta impairs interferon-gamma induction of nitric oxide synthase
117. Interferon beta normalizes suppressor cell function in dysimmune neuropathies
118. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with intereron beta
119. Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI
120. Interferon-beta inhibits activated leukocyte migration through human brain microvascular endothelial cell monolayer
121. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b
122. Incidence of exacerbations in the first 90 days of treatment with recombinant human interferon beta-1b in patients with relapsing-remitting multiple sclerosis
123. Interferon-γ secretion by peripheral blood T-cell subsets in multiple sclerosis: Correlation with disease phase and interferon-β therapy
124. IFN-gamma inhibits activation-induced expression of E- and P-selectin on endothelial cells
125. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats
126. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α 2a
127. Randomized trial of interferon b-1a in chronic inflammatory demyelinating polyradiculoneuropathy
128. Interferon-β1a in chronic inflammatory demyelinating polyneuropathy